RetinalGenix Technologies filings document public-company reporting status, financial-statement timing, and governance changes for a developmental-stage company focused on retinal imaging, genetic testing, and pharmacogenetic mapping. The record includes a Form 12b-25 notification related to the timing of its annual report and an 8-K reporting an executive officer resignation, with disclosures centered on reporting obligations, financial statement finalization, and management structure.
RetinalGenix Technologies (RTGN) filed its Q3 2025 10‑Q, reporting no revenue and a smaller quarterly net loss of $568,791 versus $644,291 a year ago. Operating expenses fell to $567,833 on lower R&D and stock‑based compensation, while interest expense was negligible.
Liquidity is strained: cash was $92 at September 30, 2025 against total liabilities of $2,179,731 and a stockholders’ deficit of $(2,172,730). The company discloses “substantial doubt” about its ability to continue as a going concern and is in discussions to raise capital and explore a potential up‑listing. Related‑party payables include $539,052 due to Sanovas as of quarter‑end.
For the nine months, net loss improved to $1,805,468 from $3,453,800 on sharply lower stock‑based compensation. RTGN sold 82,666 shares for $186,000 year‑to‑date and subsequently sold 12,000 shares for $27,000. A material weakness in internal control over financial reporting (lack of segregation of duties) remains. Common shares outstanding were 18,604,961 at November 14, 2025.
RTGN: A shareholder filed a Form 144 notice to sell up to 77,400 common shares with an aggregate market value of $247,680.00. The filing lists Alpine Securities Corporation as broker and targets an approximate sale date of November 10, 2025 on the OTCQB.
The filing notes 18,604,961 shares outstanding. It also discloses prior acquisitions and recent activity: the securities were acquired via warrant exercise dated 09/01/2018, with payment by check on 03/06/2019. Over the past three months, Bayern Capital LLC reported sales of common shares, including 8,000 for $30,718.67 on 10/24/2025, 10,100 for $36,800.27 on 10/27/2025, and 2,500 for $8,063.95 on 10/31/2025.